Depo-Provera MDL 3140: the July 27 conference is a reminder not to wait on records

The Depo-Provera meningioma litigation is moving fast enough that it can be hard to tell what matters and what is just courthouse noise. For families trying to understand whether a claim may exist, the practical takeaway is simpler: the federal MDL is large, active, and still asking for proof that ties a person’s Depo-Provera use to a meningioma diagnosis.

As of the Judicial Panel on Multidistrict Litigation’s July 1, 2026 pending actions report, MDL No. 3140 listed 5,830 pending actions and 5,916 total actions in the Northern District of Florida. The cases are assigned to U.S. District Judge M. Casey Rodgers. That count alone does not prove anyone’s individual claim. It does show that this litigation is no longer a small group of isolated filings.

The court’s own MDL 3140 page also lists a case management conference for July 27, 2026 at 9:00 a.m. Central time, with later monthly conferences on the calendar. The same page currently lists a Rule 702 motions hearing for September 18, 2026 following that day’s case management conference. Rule 702 is the federal evidence rule used when the court evaluates expert testimony. In plain English, the expert phase is where the parties fight over what science the jury will be allowed to hear.

That matters because Depo-Provera cases are not just “I used the shot and later got sick” cases. A strong review usually starts with three separate buckets of records: proof of use, proof of diagnosis, and medical history that helps explain timing and risk factors.

What a Depo-Provera claim review usually needs

The first bucket is Depo-Provera exposure. Pharmacy records, OB-GYN records, clinic notes, injection logs, insurance claims, patient portal summaries, and old appointment records can all matter. Many people received injections years ago and do not have a neat printout showing every dose. That does not automatically end the discussion, but it makes record collection more important.

The second bucket is the meningioma diagnosis. Useful records may include MRI or CT reports, neurology notes, neurosurgery notes, pathology reports if surgery was performed, radiation oncology records, and follow-up imaging. A meningioma is often described as a tumor arising from the membranes around the brain or spinal cord. Some are monitored; others require surgery or radiation. The details matter.

The third bucket is timing. Lawyers and medical experts may look at when injections began, how long use continued, when symptoms appeared, when imaging first showed a mass, whether the tumor grew, and what treatment was needed. A single missing date can slow down a review.

Why the science is being watched closely

One reason this litigation grew is a 2024 BMJ study that reported an association between prolonged use of certain progestogens and intracranial meningioma. Search summaries for the BMJ paper and related clinical statements identify injectable medroxyprogesterone acetate, the active drug in Depo-Provera, as one of the exposures studied, with an odds ratio reported around 5.55 in one analysis.

That number is important, but it should not be oversold. An association in a population study is not the same thing as proof that a specific injection caused a specific person’s tumor. The MDL still has to deal with general causation, specific causation, dose, duration, warnings, and defenses raised by Pfizer and related defendants.

For potential claimants, this is why medical records matter more than online settlement rumors. A real case review is built from documents, not guesses.

What the July 27 conference may mean for families

A case management conference is not a trial. It is usually a scheduling and status hearing. Still, in a large MDL, these conferences can affect deadlines, discovery, expert rulings, bellwether planning, and how quickly unresolved issues move forward.

Some litigation trackers have reported settlement discussions or an agreement in principle for eligible federal MDL claims. We are treating those reports carefully because public eligibility rules, payment formulas, deadlines, and claim-by-claim requirements are not the same thing as a press headline. Until a finalized process is public and applicable to a particular person, families should not assume they are automatically protected.

The safer step is to get organized now. If you used Depo-Provera or Depo-SubQ Provera and were later diagnosed with a meningioma, gather the records you can still reach. Ask pharmacies for historical profiles. Check patient portals before old messages disappear. Request imaging reports, not just appointment summaries. If you had surgery, request the operative report and pathology report. If a family member died after a meningioma diagnosis, the estate or next of kin may need death records and treatment records.

A careful next step

Not every Depo-Provera user with a meningioma will qualify for a claim, and no article can promise compensation. The facts that tend to matter include duration of use, timing of diagnosis, type and location of tumor, treatment, damages, and whether records support the history.

Mass Tort America is continuing to follow MDL 3140, including the July 27 conference, the court’s Rule 702 schedule, and any public settlement or claims-process developments. If you believe your diagnosis may be connected to Depo-Provera, a document-based review is the most useful next step.

Attorney advertising / informational notice: This article is for general information only and is not legal or medical advice. Reading it does not create an attorney-client relationship. Past results do not guarantee future outcomes. You should speak with a qualified medical professional about health decisions and a lawyer about your legal rights.